Three Reasons Why Inivata’s InVisionFirst(R) Lung is Best in Class

The holder of a BBA in marketing from the University of Georgia and an MBA from Rutgers University, Stacy Chick is an executive in biotechnology. The chief commercial officer at Inivata, Inc., Stacy Chick is leading a team of sales and marketing professionals to commercialize the company’s innovative InVisionFirst(R) Lung liquid biopsy test.

Here are three reasons why Inivata’s InVisionFirst(R) Lung is an ideal ctDNA liquid biopsy for patients with advanced non-small cell lung cancer:

- Inivata, through its partnership with local and national phlebotomy service providers, can offer mobile blood drawing services at no cost to patients. When a physician recommends the test, a mobile phlebotomy provider will contact the patient, schedule an appointment, draw a sample of the patient’s blood, and send it to the laboratory for analysis.

- InVisionFirst(R) Lung has high sensitivity of 97.8 percent. This makes it possible for laboratory technicians to analyze ctDNA to detect mutations commonly found in advanced non-small cell lung cancer.

- In advanced lung cancer cases, time is of the essence. No one wants to wait for weeks to receive their test results. InVisionFirst(R) Lung has a turnaround time of seven days, allowing doctors to act quickly and prescribe tailored treatments to patients who urgently need them.